NCT01507610View on ClinicalTrials.gov

Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Migraine
Interventions
DRUG

Sumatriptan

To compare the single-dose pharmacokinetics (PK) and relative bioavailability of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet, and 6 mg IMITREX® (sumatriptan) Subcutaneous Injection, in healthy subjects.

Trial Locations (1)

07753

Celerion, Neptune City

All Listed Sponsors
lead

Optinose US Inc.

INDUSTRY

NCT01507610 - Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects | Biotech Hunter | Biotech Hunter